In the November 2024 edition of The National Medical Journal of India, Dr. Yanamadala Muralikrishna‘s remarkable contributions to HIV treatment were highlighted, particularly his advocacy for the two-drug regimen that has transformed the landscape of HIV management globally. In a review on his book, “HIV-AIDS in India and Developing Countries”, Manish Soneja, Department of Medicine, AIIMS, said: “Dr. Yanamadala shares his own experiences and opinions throughout the book, providing a unique and personal perspective on the issue. This approach adds authenticity and depth to the narrative, though it also introduces opinions that many experts may not agree with.”
Pioneering HIV Treatment
Over two decades ago, Dr. Yanamadala Muralikrishna, a distinguished physician from Kakinada, India, introduced an innovative approach to HIV treatment: a two-drug regimen capable of reducing the HIV viral load to undetectable levels. His innovation, first presented to the global medical community in 2004, has withstood the test of time and has recently gained universal acceptance. This article traces the journey of Dr. Muralikrishna’s revolutionary approach, its validation by global health authorities, and its impact on HIV management worldwide.
HIV Treatment Revolution: From Three-Drug to Two-Drug Regimens
The Standard Until 2022
Since 1996, HIV treatment worldwide has relied on the combination of three or more antiretroviral drugs. This approach aimed to suppress the virus effectively, minimize drug resistance, and manage complications. However, the regimens often posed challenges, including high costs, side effects, and adherence difficulties.
Dr. Muralikrishna’s Breakthrough
Starting in the early 2000s, Dr. Muralikrishna began treating HIV patients with a two-drug regimen, challenging the prevailing norms. Through rigorous clinical evaluations, he demonstrated that this combination could achieve undetectable viral loads in patients who were antiretroviral-naive. His research was presented at the 13th International Symposium on HIV and Emerging Infectious Diseases in France in 2004, marking a significant milestone in the global discourse on HIV treatment.
Recognition and Global Acceptance
Validation by International Guidelines
Dr. Muralikrishna’s two-drug regimen gained global acknowledgment in recent years:
– United States HIV Treatment Guidelines: In 2022, the U.S. officially included the two-drug regimen in its treatment guidelines, recognizing its efficacy and safety.
– European AIDS Clinical Society (EACS) Guidelines: Shortly thereafter, the EACS endorsed the two-drug approach in its latest HIV treatment guidelines, cementing its status as a universal standard.
Scientific Evidence
The transition to the two-drug regimen aligns with evolving research that emphasizes efficacy in reducing viral loads, minimizing side effects, and improving patient adherence. These advantages have made it the preferred choice for newly diagnosed HIV patients, especially those with no prior antiretroviral therapy history.
HIV Treatment Guidelines: The Two-Drug Approach
Recommended Regimens
1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) + Integrase Strand Transfer Inhibitor (INSTI):
– Example: Lamivudine (3TC) + Dolutegravir (DTG).
– Requirements: HBsAg-negative patients with viral loads < 500,000 copies/mL.
– Notes: Proven to be effective with fewer side effects compared to older regimens.
2. Other Combinations:
– Specific combinations tailored to patient needs, considering co-morbidities and drug resistance.
Advantages
– Reduced drug-related toxicity.
– Simplified dosing, enhancing patient adherence.
– Lower costs, making treatment more accessible, particularly in developing countries.
Dr. Muralikrishna’s Contributions Beyond HIV
COVID-19 Awareness and Research
During the COVID-19 pandemic, Dr. Muralikrishna extended his expertise to combat the global crisis:
– Awareness Campaigns: Through Facebook and other platforms, he educated the public on home care and mild COVID-19 management, reducing fear and panic among Telugu-speaking communities.
– Research on Three-Drug COVID-19 Therapy: His findings, presented at the Global Summit on Infectious Diseases in 2021, offered practical solutions for pandemic management.
– Publications: His book, HIV-AIDS in India and Developing Countries, published in 2022, explores parallels between HIV and COVID-19, providing valuable insights for medical professionals and the public.
Impact and Legacy
Dr. Yanamadala Muralikrishna’s pioneering work in HIV treatment underscores the importance of innovation, perseverance, and scientific rigor in addressing global health challenges. His contributions have not only transformed HIV management but also inspired advancements in other areas of infectious disease treatment.
As the world continues to embrace the two-drug regimen, Dr. Muralikrishna’s legacy serves as a testament to the power of evidence-based medicine in improving patient outcomes and shaping healthcare policies worldwide. His journey from Kakinada to the global stage exemplifies how local innovation can create a global impact.
– Dr. Ismail Suhail Penukonda
